Skip to main content

Wheezing clinical trials at UC Health
1 research study open to new patients

  • Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness

    open to eligible people ages 6 months to 18 months

    The primary objective of this study is to evaluate if Broncho-Vaxom® given to high risk infants for 10 days, monthly, for two consecutive years can increase time to occurrence of the first episode of wheezing lower respiratory tract illness (WLRI) during a third observation year after therapy

    at UCSF

Last updated: